![](https://ml.globenewswire.com/media/96c701e4-af1b-4269-b10f-0510ab015d3c/small/avadel-png.png)
Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and ...
– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate regimens – – 91% reported being better able to sleep through the night after switching to LUMRYZ – – 93% of those who switched to …